Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
· Financial Post
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing clinical-stage and late-stage programs supported by human data rather than early discovery platforms with uncertain timelines. Following a period where capital heavily favored preclinical innovation, investors and acquirers are now focusing on assets that demonstrate safety signals, efficacy data and clearer pathways toward commercialization. Within this shifting landscape, companies holding diversified clinical-stage portfolios across oncology and central nervous system (CNS) indications are drawing renewed attention. One such example is Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), which recently announced expanded international intellectual property coverage for OT-101, its proprietary TGF-β antisense therapeutic platform. The development strengthens protection across neurology, oncology and CNS drug-delivery technologies aimed at crossing the blood–brain barrier. This evolving M&A environment highlights Oncotelic’s positioning within oncology and CNS innovation alongside industry leaders such as Denali Therapeutics Inc. (NASDAQ: DNLI), Roche Holdings AG (OTCMKTS: RHHBY), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) and Wave Life Sciences Ltd. (NASDAQ: WVE). Read More
Visit catcross.biz for more information.